Search research articles
Contact Us
Filters
Showing results (161-170 of 193) with videos related to
Page
of 20
Sort By:
British Journal of Haematology
|
February 9, 2022
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study
Elena Maria Elli, Ambra Di Veroli, Daniela Bartoletti, et al.
Annals of Hematology
|
January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Francesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Cancer Medicine
|
October 29, 2019
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis
Enrico Balleari, Rosa Angela Filiberti, Chiara Salvetti, et al.
Cancer
|
March 19, 2021
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice
Marino Clavio, Elena Crisà, Maurizio Miglino, et al.
Blood Advances
|
February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
Stéphane de Botton, Pierre Fenaux, Karen Yee, et al.
The New England Journal of Medicine
|
December 11, 2012
Cardiovascular events and intensity of treatment in polycythemia vera
Roberto Marchioli, Guido Finazzi, Giorgina Specchia, et al.
Cancer
|
August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib
Francesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
Leukemia Research
|
June 3, 2025
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study
Francesca Palandri, Massimo Breccia, Erika Morsia, et al.
Annals of Hematology
|
July 5, 2014
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial
Mariam G Aslanyan, Leonie I Kroeze, Saskia M C Langemeijer, et al.
Cancer
|
February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis
Francesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Page
of 20
Search research articles
Search
Showing results (161-170 of 193) with videos related to
Sort By:
Page
of 20
British Journal of Haematology
|
February 9, 2022
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study
Elena Maria Elli, Ambra Di Veroli, Daniela Bartoletti, et al.
Annals of Hematology
|
January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Francesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Cancer Medicine
|
October 29, 2019
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis
Enrico Balleari, Rosa Angela Filiberti, Chiara Salvetti, et al.
Cancer
|
March 19, 2021
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice
Marino Clavio, Elena Crisà, Maurizio Miglino, et al.
Blood Advances
|
February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
Stéphane de Botton, Pierre Fenaux, Karen Yee, et al.
The New England Journal of Medicine
|
December 11, 2012
Cardiovascular events and intensity of treatment in polycythemia vera
Roberto Marchioli, Guido Finazzi, Giorgina Specchia, et al.
Cancer
|
August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib
Francesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
Leukemia Research
|
June 3, 2025
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study
Francesca Palandri, Massimo Breccia, Erika Morsia, et al.
Annals of Hematology
|
July 5, 2014
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial
Mariam G Aslanyan, Leonie I Kroeze, Saskia M C Langemeijer, et al.
Cancer
|
February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis
Francesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Page
of 20